HMG CoA Reductase Inhibitor Fluvastatin Arrests the Development of Implanted Hepatocarcinoma in Rats

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3949-3954

  Paragh, György ^a,b   Kertai, Pal ^a   Kovacs, Péter ^a   Paragh Jr , György ^a   Fülöp, Péter ^a   Foris, Gabriella ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Chemoprevention; Fluvastatin; Hepatocarcinoma; Rat; Tumor growth inhibition

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; IMPLANTATION; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, INBRED F344;

EID: 0345305243     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Brown MS and Goldstein JL: Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21: 505-517, 1980.
2. Tobert JA, Hitzenberger G, Kukovetz WR, Holmes IB and Jones KH: Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxiymethylglutaryl-coenzyme A reductase. Atherosclerosis 41: 61-65, 1982.
3. Galton DJ: The regulation of cholesterol synthesis in human cells. Int J Obesity 5: 619-625, 1981.
4. Bard M and Dowing JF: Genetic and biochemical aspects of yeast sterol regulation involving 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Gen Microbiol 125: 415-420, 1981.
5. Bansal N, Houle AG and Melnykovych G: Comparison of dexamethasone and lovastatin (mevinolin) as growth inhibitors in cultures of T-cell driven human acute leukemia lines (CEM). Leukemia Res 13: 875-882, 1989.
6. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, Paoletti R and Soma MS: Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 87: 458-468, 1996.
7. Maltese WA, Defendini R, Green RA, Sheridan KM and Donley DK: Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 76: 1748-1754, 1985.
8. Illingworth DR: Management of hyperlipidemia: goals for the prevention of atherosclerosis. Clin Invest Med 13: 211-218, 1990.
9. Schultz S and Nyce JW: Inhibition of protein farnesyltransferase: a possible mechanism of tumor prevention by dehydroepiandro-sterone sulfate. Carcinogenesis 15: 2649-2652, 1994.
10. Cuthbert JA and Lipsky PE: Suppression of the proliferation of Ras-transformed cells by fluoromevalunate, an inhibitor of mevalonate metabolism. Cancer Res 55: 1732-1740, 1995.
11. Yuan JN, Tsai MY, Hegland J and Hunninghake DB: Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87: 147-157, 1991.
12. Levy RI, Troendle AJ and Fattu JM: A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 87: (Suppl) III45-53, 1993.
13. Kumar B, Andreatta C, Koustas WT, Cole WC, Edwards-Prasad J and Prasad KN: Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J Neurosci Res 68: 627-635, 2002.
14. Soma MR, Parolini C, Donetti E, Fumagalli R and Paoletti R: Inhibition of isoprenoid biosynthesis and arterial smooth muscle cell proliferation. J Cardiovasc Pharm 25: (Suppl 4) S20-S24, 1995.
15. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H and Nakamura H: Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-nethylgluteryl-coenzyme A reductase inhibitors. Cancer Res 61: 4885-4891, 2001.
16. Wong WW, Tan MM, Xia Z, Dimitrioulakos J, Minden MD and Penn LZ: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 7: 2067-2075, 2001.
17. Toshiyuki K, Mutsuko M, Teruo I, Masaharu T, Yoshirou M, Hitoshi A, Inoue M and Hiroyuki N: 3-hydroxy-3-methlyglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317, 2002.
18. Parker RA, Clark RW, Sit SY, Lanier TL, Grosso RA and Wright JJ: Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 31: 1271-1282, 1990.
19. Mascaro C, Ortiz JA, Ramos MM, Haro D and Hegardt FG: Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-methylglutaryl coenzyme A synthase transcription. Arch Biochem Biophys 374: 286-292, 2000.
20. Uzvolgyi E, Katona A and Kertai P: Tumor cell implantation with use of Gelaspon gelatin sponge disc. Cancer Letters 51: 1-5, 1990.
21. Kawata S, Kakimoto H, Ishiguro H, Yamasaki E, Inui Y and Matsuzawa Y: Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzme A reductase inhibitor, on survival of AH310 hepatoma bearing rats. J Cancer Res 83: 1120-1123, 1992.
22. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS and Holt PR: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117: 838-847, 1999.
23. Hawk MA, Kimberley TC, Sigling JC, Stoner GD and Ruch RJ: Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Letters 109: 217-222, 1996.
24. Lee SJ, Ha MJ, Lee J, Nguyen PM, Choi YH, Pirina F, Kang WK, Wang XF, Kim SJ and Trepel JB: Inhibition of the 3-Hydroxy-3-methylgutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 WAF1/CIP1 in human prostate carcinoma cells. J Biol Chem 273: 10618-10623, 1998.
25. Wei W and Macaulay RJB: Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. Int J Cancer 82: 430-434, 1999.
26. Vitale M, Matola T, Rossi G, Laezza Ch, Frenzi G and Bifulco M: Prenylransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and Caspase-3-like protease-dependent mechanism. Endocrinology 140: 698-704, 1999.
27. Maltese, WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4: 3319-3328, 1990.
28. Rogler, G, Lackner, KJ and Schmitz G: Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro. Basic Res Cardiol 90: 443-450, 1995.
29. Nakamura T, Nishi H, Kokusenya Y, Hirota K and Miura Y: Mechanism of antioxidative activity of fluvastatin-detemination of the active position. Chem Pharm Bull 48: 235-237, 2000.
30. Nakashima A, Ohtawa M, Iwasaki K, Wada M, Kuroda N and Makashima K: Inhibitory effects of fluvastatin and its metabolites on the formation of several oxygen species. Life Sci 69: 131-139, 2001.
31. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H and Iguchi A: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155: 347-357, 2001.
32. Imaeda A, Tanigawa T, Aoki T, Kondo Y, Nakamura N and Yoshikawa T: Antioxidative effects of fluvastatin and its metabolites against oxidative DNA damage in mammalian cultured cells. Free Radic Res 35: 789-801, 2001.
33. Ikeda U, Shimpo M, Ikeda M, Minota S and Shimada K: Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 38: 69-77, 2001.
34. Nakamura T, Nishi H, Koksenya Y, Hirota K and Miura Y: Mechanism of antioxidative activity of fluvastatin-determination of the active position. Chem Pharm Bull 48: 235-237, 2000.
35. Elsdale T and Bard J: Collagen substrate for studies on cell behavior. J Cell Biol 54: 626-637, 1972.